Back to Peptide Index

CJC-1295

LongevityEvidence Level: researchResearch Use Only; not an approved medication on the market.
Peptide #35

CJC-1295 is a long-acting analog of Growth Hormone-Releasing Hormone (GHRH) designed to boost growth hormone (GH) secretion in a sustained manner. It is often referred to as a GHRH analog with DAC (Drug Affinity Complex) and is significant for its ability to raise IGF-1 levels for prolonged periods and enhance pulsatile GH release while preserving the natural rhythm of GH secretion.

Alternative Names:

CJC-1295 with DAC, Modified GRF 1-29

Overview

CJC-1295 is a peptide that boosts natural growth hormone production, often studied for muscle recovery, fat loss, and healthy aging.

How It Works

CJC-1295 works by binding to GHRH receptors, triggering GH release. The DAC component allows prolonged presence in the bloodstream, maintaining GH pulsatility.

Clinical Effects

Increased protein synthesis, cartilage and bone growth stimulation, enhanced fat breakdown, improved sleep, increased lean body mass, reduced fat mass.

Therapeutic Applications

Growth Hormone Deficiency, Functional Decline in Elderly, Muscle or Bone Disorders, Metabolic Syndrome & Obesity, Burns or Severe Injuries, HIV-Associated Lipodystrophy.

Research Studies

Clinical Trials

Early trials aimed at treating GH-deficient adults showed promising IGF-1 elevation.

Preclinical Studies

Animal models of osteoporosis have used continuous GH or GHRH analogs to see improvements in bone formation.

Frequently Asked Questions

How is CJC-1295 different from Sermorelin or other GHRH? CJC-1295 starts raising GH within hours of injection. What are the side effects of CJC-1295? Can CJC-1295 be combined with Ipamorelin or other peptides? Is there a risk of shutting down natural GH production with CJC-1295? Who should not use CJC-1295?

Quick Information

Half-Life:

5–8 days

Metabolism:

Avoids rapid kidney clearance and enzymatic breakdown by binding to albumin.

Safety Information

Safety Profile

Caution advised for those with cancer, diabetes, or serious medical conditions. Monitoring recommended for glucose levels in diabetic individuals.

Contraindications

Side Effects: Injection site reactions, water retention, slight edema, joint pain, carpal tunnel syndrome-like symptoms, light-headedness, potential elevated blood sugar. Safety Profile: Caution advised for those with cancer, diabetes, or serious medical conditions. Monitoring recommended for glucose levels in diabetic individuals.

Side Effects

Injection site reactions, water retention, slight edema, joint pain, carpal tunnel syndrome-like symptoms, light-headedness, potential elevated blood sugar.

Research References

Teichman SL et al. “Prolonged Stimulation of GH and IGF-I by CJC-1295 in Healthy Adults.” J Clin Endocrinol Metab. 2006. Ionescu M & Frohman LA. “GH Secretion Persists During Continuous Stimulation by CJC-1295.” J Clin Endocrinol Metab. 2006. Strasburger CJ et al. “Endocrine and Metabolic Effects of Sustained GHRH Analog Administration.” Hormone Research. 2008. Yuen KCJ et al. “Effects of a Long-acting GHRH Analog in HIV Lipodystrophy.” Pituitary. 2013. Melmed S. “Medical Progress: Acromegaly and GH physiology.” N Engl J Med. 2006.

Additional Resources

View Source